Breaking News Instant updates and real-time market news.

BIIB

Biogen

$313.03

7.25 (2.37%)

10:16
10/03/16
10/03
10:16
10/03/16
10:16

Biogen potential trading opportunity into year-end, says BMO Capital

BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.

  • 26

    Oct

  • 06

    Nov

BIIB Biogen
$313.03

7.25 (2.37%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.

TODAY'S FREE FLY STORIES

18:15
09/25/17
09/25
18:15
09/25/17
18:15
General news
Breaking General news story  »

Minneapolis Federal…

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

18:13
09/25/17
09/25
18:13
09/25/17
18:13
Downgrade
Cardtronics rating change  »

Cardtronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVTY

Invuity

$7.80

-0.5 (-6.02%)

18:10
09/25/17
09/25
18:10
09/25/17
18:10
Recommendations
Invuity analyst commentary  »

Invuity's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Nov

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

, UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

18:05
09/25/17
09/25
18:05
09/25/17
18:05
Hot Stocks
CBO: Graham-Cassidy ACA repeal bill to reduce number of insured by 'millions' »

The Congressional Budget…

MOH

Molina Healthcare

$64.54

-0.78 (-1.19%)

UNH

UnitedHealth

$191.75

-1.28 (-0.66%)

CNC

Centene

$90.33

-1.89 (-2.05%)

WCG

WellCare

$164.15

-3.01 (-1.80%)

CI

Cigna

$181.44

-1.3 (-0.71%)

ANTM

Anthem

$181.50

-1.36 (-0.74%)

HNT

Health Net

HUM

Humana

$237.21

-1.88 (-0.79%)

AET

Aetna

$151.98

-1.59 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

GPC

Genuine Parts

$93.22

5.24 (5.96%)

18:04
09/25/17
09/25
18:04
09/25/17
18:04
Recommendations
Genuine Parts analyst commentary  »

Genuine Parts acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 19

    Oct

  • 30

    Oct

AA

Alcoa

$45.29

-0.09 (-0.20%)

, FCX

Freeport McMoRan

$13.89

-0.17 (-1.21%)

17:55
09/25/17
09/25
17:55
09/25/17
17:55
Recommendations
Alcoa, Freeport McMoRan, Teck Resources, Newmont Mining, Warrior Met Coal, Cleveland-Cliffs analyst commentary  »

Morgan Stanley raising…

AA

Alcoa

$45.29

-0.09 (-0.20%)

FCX

Freeport McMoRan

$13.89

-0.17 (-1.21%)

TECK

Teck Resources

$21.24

-0.72 (-3.28%)

NEM

Newmont Mining

$38.63

0.74 (1.95%)

HCC

Warrior Met Coal

$24.11

0.76 (3.25%)

CLF

Cleveland-Cliffs

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

  • 20

    Oct

  • 26

    Oct

17:55
09/25/17
09/25
17:55
09/25/17
17:55
Conference/Events
Federal Reserve Bank of Minneapolis President participates in a discussion »

Minneapolis Federal…

FTK

Flotek

$5.40

0.04 (0.75%)

17:49
09/25/17
09/25
17:49
09/25/17
17:49
Earnings
Flotek cuts Q3 revenue view by $5M, consensus $90.9M »

Flotek announced impacts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 14

    Nov

  • 16

    May

NBLX

Noble Midstream

$54.11

3.75 (7.45%)

17:44
09/25/17
09/25
17:44
09/25/17
17:44
Recommendations
Noble Midstream analyst commentary  »

Noble Midstream guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 31

    Oct

FB

Facebook

$162.87

-7.67 (-4.50%)

17:38
09/25/17
09/25
17:38
09/25/17
17:38
Periodicals
Russia looked to 'exploit' divisions in U.S. populace with Facebook ads, WP says »

The collection of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

ASNA

Ascena Retail

$2.17

0.07 (3.33%)

, SNX

Synnex

$116.50

0.4 (0.34%)

17:35
09/25/17
09/25
17:35
09/25/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$2.17

0.07 (3.33%)

SNX

Synnex

$116.50

0.4 (0.34%)

RHT

Red Hat

$105.76

-0.54 (-0.51%)

ACTA

Actua

$12.25

-0.1 (-0.81%)

PRQR

ProQR Therapeutics

$6.45

0.25 (4.03%)

GNCA

Genocea

$5.33

0.04 (0.76%)

KDMN

Kadmon

$3.79

0.27 (7.67%)

QEP

QEP Resources

$8.88

0.51 (6.09%)

TXMD

TherapeuticsMD

$6.06

-0.11 (-1.78%)

BIOP

Bioptix

$4.11

-0.16 (-3.75%)

CSGP

CoStar Group

$279.20

-1.62 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 27

    Sep

  • 16

    Oct

  • 17

    Oct

  • 03

    Nov

  • 26

    Sep

GKOS

Glaukos

$31.26

-0.93 (-2.89%)

17:30
09/25/17
09/25
17:30
09/25/17
17:30
Hot Stocks
Breaking Hot Stocks news story on Glaukos »

James E. Flynn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOP

Bioptix

$4.11

-0.16 (-3.75%)

17:28
09/25/17
09/25
17:28
09/25/17
17:28
Hot Stocks
Bioptix changes state of incorporation to Nevada from Colorado »

Bioptix said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$254.32

-2.13 (-0.83%)

17:26
09/25/17
09/25
17:26
09/25/17
17:26
Hot Stocks
Boeing and Qatar Airways announce order valued at $2.16B »

Boeing and Qatar Airways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CLXT

Calyxt

$26.54

0.82 (3.19%)

17:25
09/25/17
09/25
17:25
09/25/17
17:25
Hot Stocks
Calyxt: Herbicide-tolerant wheat, oil composition canola move to Phase 1 »

Calyxt announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MNK

Mallinckrodt

$35.25

0.42 (1.21%)

17:03
09/25/17
09/25
17:03
09/25/17
17:03
Earnings
Mallinckrodt sees InfaCare acquisition 15c-20c dilutive to FY17 adjusted EPS »

Mallinckrodt announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

FTI

TechnipFMC

$27.02

0.19 (0.71%)

17:02
09/25/17
09/25
17:02
09/25/17
17:02
Hot Stocks
TechnipFMC implements share repurchase of up to $500M »

TechnipFMC announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

GNCA

Genocea

$5.33

0.04 (0.76%)

17:01
09/25/17
09/25
17:01
09/25/17
17:01
Hot Stocks
Breaking Hot Stocks news story on Genocea 

Genocea trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

TXMD

TherapeuticsMD

$6.06

-0.11 (-1.78%)

16:53
09/25/17
09/25
16:53
09/25/17
16:53
Syndicate
TherapeuticsMD files to sell 12.4M shares of common stock »

J.P. Morgan is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 03

    Nov

LLL

L3 Technologies

$189.32

0.04 (0.02%)

16:52
09/25/17
09/25
16:52
09/25/17
16:52
Hot Stocks
L3 Technologies files protest with GAO related to Fort Rucker contract »

L3 Technologies announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRI

Apricus Biosciences

$1.73

0.05 (2.98%)

16:50
09/25/17
09/25
16:50
09/25/17
16:50
Syndicate
Apricus Biosciences requests withdrawal of registration statement »

The company confirms that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

CDXS

Codexis

16:48
09/25/17
09/25
16:48
09/25/17
16:48
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Vivo Ventures lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 29

    Sep

  • 16

    Nov

AGRO

Adecogro

$10.05

-0.12 (-1.18%)

16:45
09/25/17
09/25
16:45
09/25/17
16:45
Hot Stocks
Adecoagro refinances majority of debt »

Adecoagro announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIBT

RiceBran

$1.21

-0.03 (-2.42%)

16:44
09/25/17
09/25
16:44
09/25/17
16:44
Hot Stocks
Breaking Hot Stocks news story on RiceBran »

Continental Grain reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

CLDR

Cloudera

$16.08

-0.83 (-4.91%)

16:42
09/25/17
09/25
16:42
09/25/17
16:42
Syndicate
Cloudera announces 3M share follow-on offering »

Cloudera announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.